PHASE 2 STUDY OF TELATINIB IN COMBINATION WITH CAPECITABINE AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED CANCER OF THE STOMACH OR GASTRO-ESOPHAGEAL JUNCTION (GEJ)

被引：0
|
作者：
Alsina, M. [1 ]
Ajani, J. A. [2 ]
Ko, A. H. [3 ]
Garcia De Paredes, M. L. [4 ]
Rivera, F. [5 ]
Schwartzberg, L. [6 ]
Phan, A. T. [2 ]
Whiteside, M. [7 ]
Kunkel, L. A. [6 ,8 ]
Tabernero, J. [9 ]
机构：
[1] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[2] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol Dept, Houston, TX 77030 USA
[3] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Hematol Oncol, San Francisco, CA USA
[4] Hosp Univ Ramon y Cajal, Madrid, Spain
[5] Hosp Univ Marques de Valdecilla, Dept Med Oncol, Santander, Spain
[6] West Clin, Memphis, TN USA
[7] ACT Biotech Inc, Clin Operat, San Francisco, CA USA
[8] ACT Biotech Inc, Clin Dev, San Francisco, CA USA
[9] Vall dHebron Univ Hosp, Med Oncol Serv, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：229 / 229
页数：1
相关论文
共 50 条
  • [1] Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEI).
    Ko, A. H.
    Tabernero, J.
    Garcia De Paredes, M.
    Rivera, F.
    Schnell, F. M.
    Baker, J. S.
    Phan, A. T.
    Alsina, M.
    Patel, K.
    Ajani, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Phase II study of capecitabine and cisplatin as first-line chemotherapy in patients with advanced esophageal cancer
    Hong, Yong S.
    Lee, Hyo R.
    Hwang, In G.
    Lee, Sang C.
    Lee, Jeeyun
    Park, Joon O.
    Park, Young S.
    Lim, Ho Y.
    Im, Young-Hyuck
    Kang, Won K.
    ANNALS OF ONCOLOGY, 2006, 17 : 314 - 314
  • [3] Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer
    Alsina, M.
    Ko, A. H.
    De Paredes, M. Garcia
    Rivera, F.
    Schwartzberg, L. S.
    Fattaey, A.
    Kunkel, L. A.
    Tabernero, J.
    Ajani, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Cascinu, S.
    Rojas, Llimpe F.
    Artale, S.
    Schinzari, G.
    Giaquinta, S.
    Mutri, V
    Martoni, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 9 - 9
  • [5] Afatinib in combination with cisplatin and 5-fluorouracil (5-FU) as first line treatment in inoperable gastric and gastro-esophageal junction (GEJ) cancer: A phase II study by the Hellenic Cooperative Oncology Group
    Makatsoris, T.
    Samantas, E.
    Manousou, K.
    Karavasilis, V.
    Aravantinos, G.
    Tryfonopoulos, D.
    Psyrri, A.
    Pectasides, D. G.
    Pazarli, E.
    Petraki, C.
    Tsipoura, A.
    Kaklamanos, I. G.
    Fountzilas, G.
    Pentheroudakis, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Kim, Chul
    Lee, Jae-Lyun
    Choi, Yoon Hee
    Kang, Byung Woog
    Ryu, Min-Hee
    Chang, Heung Moon
    Kim, Tae Won
    Kang, Yoon-Koo
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 306 - 315
  • [7] Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Kim, C.
    Lee, J.
    Choi, Y.
    Kang, B.
    Ryu, M.
    Chang, H.
    Kim, T.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Chul Kim
    Jae-Lyun Lee
    Yoon Hee Choi
    Byung Woog Kang
    Min-Hee Ryu
    Heung Moon Chang
    Tae Won Kim
    Yoon-Koo Kang
    Investigational New Drugs, 2012, 30 : 306 - 315
  • [9] Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Kim, C.
    Lee, J.
    Choi, Y.
    Kang, B.
    Ryu, M.
    Ryoo, B.
    Chang, H.
    Kim, T.
    Kang, Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 379 - 379
  • [10] Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study)
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Llimpe, F. L. Rojas
    Cascinu, S.
    Giaquinta, S.
    Schinzari, G.
    Mutri, V.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345